Physicians' Academy for Cardiovascular Education

Bempedoic Acid

Bempedoic Acid is a novel nonstatin drug that inhibits the cholesterol biosynthesis. In this section we follow the scientific news, literature and education

LDL-c goal attainment after STEMI with early combination therapy

Literature - Feb. 2, 2023 - Makhmudova U et al. - Clin Res Cardiol. 2023

With early initiation of atorvastatin 80 mg plus ezetimibe 10 mg, and escalation with bempedoic acid or PCSK9i if needed, all 85 patients hospitalized for STEMI achieved the 2019 ESC/EAS Guidelines LDL-c target.

A decade of innovation, guidelines, and paradigm shifts in LDL-c management

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.

LDL-c response to bempedoic acid using statin intensity categories

Literature - Oct. 31, 2022 - Ballantyne CM et al. - J Am Heart Assoc. 2022

In a post-hoc analysis of 4 RCTs, a ≥30% LDL-c reduction with bempedoic acid was seen in 25% of statin-treated patients and in more than half of statin-naïve patients. Factors associated with this reduction were also assessed.

Expert consensus decision pathway on nonstatin therapies for LDL-c lowering

News - Oct. 10, 2022

The Journal of the American College of Cardiology has published the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD
Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.

Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD
Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.

Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.

Network meta-analysis of LLTs in patients with hypercholesterolemia and high CV risk

Literature - July 28, 2022 - Burnett H, et al. - Curr Med Res Opin. 2022

There have been no direct comparative studies of inclisiran, evolocumab, alirocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia and increased cardiovascular risk receiving maximal tolerated statin therapy. A network meta-analysis may provide further insight.

Long-term and safe reduction of LDL-c levels with bempedoic acid

Literature - May 9, 2022 - Ballantyne CM, et al. - Am J Cardiol. 2022

In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.

Lipid management and the potential role of bempedoic acid

10' education - Apr. 26, 2022 - Rens Reeskamp, MD, PhD
Bempedoic acid has been approved by the FDA in 2020, but what is the potential place of bempedoic acid in the arsenal of lipid-lowering therapies?

Bempedoic acid has been approved by the FDA in 2020, but what is the potential place of bempedoic acid in the arsenal of lipid-lowering therapies? With question to test your knowledge.

Bempedoic acid lowers LDL-c safely in subgroups of patients

News - Apr. 19, 2022

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Use of lipid lowering therapy in patients at high and very high CV risk in Europe

News - Aug. 31, 2021

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.